News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Bio Report logo
The Bio Report: A Rapid Onset Nasal Spray to Treat Mental Health Conditions
Read
The Biotech Project
The Biotech Project: Featuring Shawn Singh
Read
BioSpace Logo
Combatting the Mental Health Crisis with an Acute Treatment Nasal Spray
Read

Press Releases

Goldie Hawn to lead discussion on supporting mental health around the globe with preeminent C-suite executives, politicians, nonprofit leaders and entrepreneurs on the importance of mental health SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 20, 2022-- Vistagen (Nasdaq: VTGN), a late
In healthy subjects, intranasal administration of PH94B activated nasal chemosensory cells, rapidly reduced sympathetic tone, and provided rapid self-reported calmness SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 19, 2022-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous
Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc.